Cassava Sciences, Inc. (NASDAQ:SAVA – Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors purchased 18,755 put options on the stock. This is an increase of approximately 63% compared to the typical volume of 11,523 put options.
Analyst Upgrades and Downgrades
Several research firms have commented on SAVA. Rodman & Renshaw reaffirmed a “buy” rating and issued a $107.00 price target on shares of Cassava Sciences in a report on Thursday, August 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Cassava Sciences in a report on Tuesday, August 13th.
View Our Latest Research Report on SAVA
Hedge Funds Weigh In On Cassava Sciences
Cassava Sciences Price Performance
Shares of NASDAQ SAVA opened at $28.49 on Friday. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -13.10 and a beta of -0.63. The firm’s 50 day simple moving average is $25.98 and its 200-day simple moving average is $21.76. Cassava Sciences has a 12 month low of $8.79 and a 12 month high of $42.20.
Cassava Sciences (NASDAQ:SAVA – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.44) by $0.57. During the same quarter last year, the business posted ($0.63) EPS. Analysts anticipate that Cassava Sciences will post -5.7 earnings per share for the current fiscal year.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Read More
- Five stocks we like better than Cassava Sciences
- Health Care Stocks Explained: Why You Might Want to Invest
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- What Does a Stock Split Mean?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Why Invest in High-Yield Dividend Stocks?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.